Glioblastoma (GBM) is the most common and aggressive primary brain tumor. The
identification of novel molecular prognostic markers of GBM has recently been an area of
great interest in neuro-oncology. The methylation status of the MGMT gene promoter is
currently a promising molecular prognostic marker, but some controversial data have
precluded its clinical use. We analyzed MGMT methylation by methylation-specific PCR in
90 GBM patients from four Portuguese hospitals, uniformly treated with radiotherapy …

Several molecular markers have been proposed as predictors of outcome in patients with
glioblastomas. We investigated the prognostic significance of $ O^ 6$-methylguanine-DNA
methyltransferase (MGMT) promoter methylation and TP53 mutation status dependent on
isocitrate dehydrogenase 1 (IDH1) mutation in glioblastoma patients. A cohort of 78 patients
with histologically confirmed glioblastomas treated with radiation therapy and chemotherapy
were reviewed retrospectively. We evaluated the prognostic value of MGMT promoter …